Covid 19 Research using Clinical Trials (Home Page)
Extra blood sampleWiki
Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation
Correlated Drug Terms (4)
Correlated MeSH Terms (4)
Correlated HPO Terms (1)
|
Name (Synonyms) |
Correlation |
HP:0011947 | Respiratory tract infection HPO | 0.19 |
There is one clinical trial.
Clinical Trials
The COVID-19 outbreak has led to a significant increase in the number of patients admitted to
intensive care for respiratory distress. Early data indicate a particularly high risk of
thrombotic risk to viral lung disease, particularly in the most severe patients, with a
particularly high incidence of pulmonary embolism. Catheter thrombosis and extra-renal
purification filters are also abnormally common. These thrombotic complications could
contribute to the mortality observed in this pathology. The introduction of early curative
anticoagulation in the most severe patients has just been proposed by the perioperative
hemostasis interest group
Biologically, a significant proportion of patients hospitalized in intensive care have a
marked biological inflammatory syndrome, associated with signs of activation of clotting (a
frank increase in D-dimers). The presence of circulating anticoagulants is common.
Interestingly, thrombocytosis, normally observed in such inflammatory syndromes, is absent.
In this context, it seems legitimate to explore these patients from a hemostasis perspective
to identify the factors that cause this thrombotic over-risk, in order to minimize the
occurrence of these complications.
NCT04359992 COVID-19 Infection Other: Extra blood sample
Primary Outcomes
Measure: Platelet activation intensity with the occurrence of clinical thrombotic complications
Time: Change of platelet activity from admission's day in intensive care unit to 2 days and 7 days
No related HPO nodes (Using clinical trials)